var data={"title":"Ibalizumab-uiyk: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ibalizumab-uiyk: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/822579?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ibalizumab-uiyk-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ibalizumab-uiyk: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51256093\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Trogarzo</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51196295\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Anti-CD4 Monoclonal Antibody;</li>\n      <li>\n        Antiretroviral, Monoclonal Antibody;</li>\n      <li>\n        Antiretroviral, Post-Attachment Inhibitor;</li>\n      <li>\n        Monoclonal Antibody</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51235795\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>HIV-1 infection:</b> IV: Initial: 2,000 mg as a single dose, followed by a maintenance dose of 800 mg every 14 days thereafter</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Missed dose:</i> If a maintenance dose (800 mg) is missed by &ge;3 days beyond the originally scheduled dosing day, a loading dose (2,000 mg) should be given as soon as possible. Resume maintenance dosing every 14 days thereafter.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51236326\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51236327\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51235796\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51256094\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Trogarzo: 150 mg/mL (1.33 mL) [contains polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51256092\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51223045\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Each 2 mL vial delivers approximately 1.33 mL containing 200 mg of ibalizumab-uiyk.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51193524\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Trogarzo: FDA approved March 2018; anticipated availability is April 2018.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51235799\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: For IV administration only. Do <b>not</b> administer IV push or bolus. Administer in the cephalic vein, or if not accessible, an appropriate vein elsewhere may be used.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Administer initial infusion (loading dose) over &ge;30 minutes. Observe patient for 1 hour after completion of initial infusion. If <b>no</b> infusion-associated adverse reactions are observed, subsequent infusions (maintenance doses) may be administered over &ge;15 minutes and post-infusion observation time may be reduced to 15 minutes. Flush with 30 mL NS after completion of each infusion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51196297\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>HIV-1 infection:</b> Treatment of HIV-1 infection in combination with other antiretrovirals in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51235782\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51219107\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Reactions reported with combination therapy.</p>\n    <p style=\"text-indent:0em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Increased serum glucose (&gt;250 mg/dL: 3%), increased uric acid (&gt;12 mg/dL: 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (8%), increased serum lipase (&gt;3 x ULN: 5%), nausea (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Decreased neutrophils (&lt;0.6 x 109 cells/L: 5%), leukopenia (&lt;1.5 x 10<sup>9</sup> cells/L: 5%), decreased hemoglobin (&lt;8.5 g/dL: 3%), decreased platelet count (&lt;50,000/mm<sup>3</sup>: 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum bilirubin (&ge;2.6 x ULN: 5%), increased direct serum bilirubin (&gt; ULN: 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased serum creatinine (&gt;1.8 x ULN or 1.5 x baseline: 10%)</p>\n    <p style=\"text-indent:0em;\">&lt;1%, postmarketing, and/or case reports: Antibody development, immune reconstitution syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51196298\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">There are no contraindications listed in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51235786\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Concerns related to adverse effects:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immune reconstitution inflammatory syndrome: Patients may develop immune reconstitution inflammatory syndrome resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment; further evaluation and treatment may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infusion-associated reactions: May occur; observe patients for 1 hour after completion of infusion for at least the first infusion. If no infusion-associated reactions are observed after the first infusion, may reduce post-infusion observation time to 15 minutes for subsequent infusions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Disease-related concerns:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Use is not recommended in antiretroviral therapy-na&iuml;ve patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Dosage form specific issues:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Contains polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51223574\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51223571\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=117178&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab. <i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51235784\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Animal reproduction studies have not been conducted. Monoclonal antibodies are known to cross the placenta and fetal exposure to ibalizumab-uiyk may be expected.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Health care providers are encouraged to enroll pregnant females exposed to ibalizumab-uiyk as early in pregnancy as possible in the Antiretroviral Pregnancy Registry (1-800-258-4263 or www.APRegistry.com). Health care providers caring for HIV-infected females and their infants may contact the National Perinatal HIV Hotline (888-448-8765) for clinical consultation (HHS [perinatal] 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51235785\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">It is not known if ibalizumab-uiyk is present in breast milk; however, endogenous human immunoglobulins are present.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Maternal or infant antiretroviral therapy does not completely eliminate the risk of postnatal HIV transmission. In addition, multiclass-resistant virus has been detected in breastfeeding infants despite maternal therapy. Therefore, in the United States, where formula is accessible, affordable, safe, and sustainable, and the risk of infant mortality due to diarrhea and respiratory infections is low, females with HIV infection should completely avoid breastfeeding to decrease the potential transmission of HIV (HHS [perinatal] 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51235802\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CD4 count, HIV RNA plasma levels</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51235791\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Ibalizumab-uiyk, a recombinant humanized monoclonal antibody, is a post-attachment inhibitor. It blocks HIV-1 from infecting CD4<sup>+</sup> T cells by binding to domain 2 of CD4<sup>+</sup> cell receptors leading to a conformational change that blocks the interaction of gp120 and HIV co-receptors; it is active against CCR5 and CXCR4 isolates. The selective binding to domain 2 of the CD4<sup>+</sup> cells allows ibalizumab-uiyk to block HIV entry without causing immunosuppression or depleting CD4<sup>+</sup> cell counts (Iacob 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51235792\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 4.8 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 3.1 to 3.3 days (Jacobson 2009)</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics.</i> 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibalizumab-uiyk-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep.</i> 1984;33(14):198-199.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibalizumab-uiyk-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission. Recommendations for the use of antiretroviral drugs in pregnant women with HIV infection and interventions to reduce perinatal HIV transmission in the United States. Department of Health and Human Services. Available at: <a href=\"https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf\" target=\"_blank\">https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf</a>. Updated November 14, 2017. Accessed December 21, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Iacob SA, Iacob DG. Ibalizumab targeting CD4 receptors, an emerging molecule in HIV therapy. <i>Front Microbiol.</i> 2017;8:2323.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibalizumab-uiyk-drug-information/abstract-text/29230203/pubmed\" target=\"_blank\" id=\"29230203\">29230203</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis.</i> 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibalizumab-uiyk-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jacobson JM, Kuritzkes DR, Godofsky E, et al. Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults. <i>Antimicrob Agents Chemother.</i> 2009;53(2):450-457.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibalizumab-uiyk-drug-information/abstract-text/19015347/pubmed\" target=\"_blank\" id=\"19015347\">19015347</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis.</i> 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibalizumab-uiyk-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet.</i> 1995;345(8960):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibalizumab-uiyk-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trogarzo (ibalizumab-uiyk) [prescribing information]. Irvine, CA: TaiMed Biologics USA Corp; March 2018.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 117178 Version 3.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F51256093\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F51196295\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F51235795\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F51236326\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F51236327\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F51235796\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F51256094\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F51256092\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F51223045\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F51193524\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F51235799\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F51196297\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F51235782\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F51219107\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F51196298\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F51235786\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F51223574\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F51223571\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F51235784\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F51235785\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F51235802\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F51235791\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F51235792\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/117178|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ibalizumab-uiyk-patient-drug-information\" class=\"drug drug_patient\">Ibalizumab-uiyk: Patient drug information</a></li></ul></div></div>","javascript":null}